Direct comparison
Blanket Consent vs. Broad Consent
Broad consent (45 CFR 46.116(d)) is a regulated IRB pathway with required disclosures; blanket consent is informal and unrestricted.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · included with Regulatory Radar
Ask about Blanket Consent vs. Broad Consent
Ask CASRAI answers research-administration questions and cites the passages behind every claim — and says so when the corpus does not cover something, instead of guessing. It comes with a Regulatory Radar subscription at $29 a month, alongside the daily digest of regulatory changes and the dashboard of what changed.
150 questions a day, on this site, over the API, or inside your own tools through the CASRAI MCP server.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do Blanket consent, Broad consent compare side by side?
The table below compares Blanket consent, Broad consent across 7 procurement-relevant dimensions, from regulatory status through compliance risk if conflated.
Side-by-side comparison
| Dimension | Blanket consent | Broad consent |
|---|---|---|
| Regulatory status | Not defined in the Common Rule, FDA regulations, or ICH E6 -- an informal, descriptive term. | Formally defined and regulated: 45 CFR 46.116(d), created by the 2018 revised Common Rule. |
| Scope of future use | Essentially unrestricted -- donation for any future research, as the term is generally used in the bioethics literature. | Bounded by a general description of research types the subject actually agreed to, even though specific future studies aren’t named. |
| Required disclosures | None specified -- content varies by institution, with no regulatory minimum. | Mandatory elements under 46.116(d): research-type description, information/biospecimen description, storage duration, non-notification statement, results-disclosure statement, contact information, plus standard 46.116(b) elements. |
| Ongoing oversight of secondary use | Not built in by definition -- may or may not include independent review, depending on institutional practice. | IRB review of each secondary study for fit within the agreed scope is the standard operating assumption. |
| Effect of refusal | No regulatory consequence defined -- depends entirely on institutional policy. | If refused, an IRB cannot later waive consent for that subject’s data/biospecimens under the 46.116(f) waiver pathway. |
| Typical use context | Loose shorthand in biobanking/bioethics discussion, sometimes used (imprecisely) as a synonym for broad consent. | The specific consent form/process an IRB reviews and approves for biobanks, repositories, and secondary-research programs. |
| Compliance risk if conflated | Labeling an actually-unrestricted process as "broad consent" overstates the protections built into it. | A form labeled "blanket consent" that skips 46.116(d)’s required elements may not legally qualify as broad consent at all. |
Common questions
Common questions about Blanket consent vs Broad consent
Is blanket consent legal under the Common Rule?
+
There is no Common Rule provision called "blanket consent." An IRB reviewing a consent process described that way needs to determine whether it actually meets 45 CFR 46.116(d)’s broad-consent requirements (if it’s meant to support a waiver of study-specific consent for secondary research) or whether it needs to be handled as a different, non-broad-consent informed-consent process.
Can broad consent and blanket consent be used interchangeably in an IRB protocol?
+
No. Using them interchangeably risks either understating what a truly unrestricted process requires, or overstating the protections in a process that hasn’t actually satisfied 46.116(d)’s specific disclosure elements. Protocols and consent forms should use "broad consent" only when the process genuinely meets that regulatory checklist.
What happens if a research subject refuses broad consent?
+
Under 45 CFR 46.116(e)-(f), if a subject was asked for broad consent and refused, an IRB cannot use the 46.116(f) waiver-of-consent pathway to bring that subject’s existing data or biospecimens into a secondary study anyway.
Does broad consent require IRB review of every secondary study?
+
The standard model is that the IRB reviews each proposed secondary use for fit within the scope the subject was told about at the time of broad consent -- broad consent is not a one-time approval for unlimited, unreviewed future use.
Going deeper
